Work

A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.11562

Authors: Matthew Ingham, Michelle R. Mahoney, Fabrizio Remotti, Ardaman Shergill, Mark Andrew Dickson, Richard F. Riedel, Steven Attia, Anthony D. Elias, David A. Liebner, Mark Agulnik, Katherine Anne Thornton, Varun Monga, Brian Andrew Van Tine, Gary K. Schwartz, William D. Tap

Institutions: Columbia University Irving Medical Center, Mayo Clinic, University of Illinois Chicago, Memorial Sloan Kettering Cancer Center, Duke Medical Center, Mayo Clinic in Florida, University of Colorado Cancer Center, The Ohio State University, Northwestern University, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Washington University in St. Louis

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W3031675467

Cites:

Cited by: 7

Related to: 10